RetroSearch Browse

Showing content from https://en.wikipedia.org/wiki/DS-1_(drug) below:

From Wikipedia, the free encyclopedia

Chemical compound

Pharmaceutical compound

DS-1 is a drug from the imidazopyridine family, which is the first drug developed that acts as a GABA_A receptor positive allosteric modulator (PAM) selective for the α4 β3 δ subtype, which is not targeted by other GABA_A receptor PAMs such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 are useful in the study of this receptor subtype.^[1]^[2]^[3]

^ Wafford KA, van Niel MB, Ma QP, Horridge E, Herd MB, Peden DR, et al. (January 2009). "Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus". Neuropharmacology. 56 (1): 182–189. doi:10.1016/j.neuropharm.2008.08.004. PMID 18762200. S2CID 207224202.
^ Yakoub K, Jung S, Sattler C, Damerow H, Weber J, Kretzschmann A, et al. (March 2018). "Structure-Function Evaluation of Imidazopyridine Derivatives Selective for δ-Subunit-Containing γ-Aminobutyric Acid Type A (GABA_A) Receptors". Journal of Medicinal Chemistry. 61 (5): 1951–1968. doi:10.1021/acs.jmedchem.7b01484. PMID 29451785.
^ Solomon VR, Tallapragada VJ, Chebib M, Johnston GA, Hanrahan JR (June 2019). "GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators". European Journal of Medicinal Chemistry. 171: 434–461. doi:10.1016/j.ejmech.2019.03.043. PMID 30928713. S2CID 89619321.